bevacizumab + imatinib mesylate

This is a combination of two targeted cancer therapies: bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis, and imatinib mesylate, a small molecule tyrosine kinase inhibitor that targets BCR-ABL, platelet-derived growth factor receptors (PDGFR), c-Kit, and other kinases. The rationale behind combining these agents is to simultaneously inhibit tumor angiogenesis (via VEGF blockade) and disrupt tumor cell signaling pathways critical for proliferation and survival (via tyrosine kinase inhibition). This combination has been studied in clinical trials primarily in metastatic melanoma[1], gastrointestinal stromal tumors (GIST)[6], and preclinical models of colorectal cancer[2]. While the regimen can be administered safely at standard doses of each agent, significant clinical benefit has not been consistently demonstrated in melanoma or GIST patients. Preclinical data suggest potential synergistic effects on tumor vasculature normalization.

Other names

bevacizumab and imatinibbevacizumab plus imatinib mesylate